Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer

Clinical Breast Cancer

Volumn 12, Issue 1, 2012, Pages 19-29

  Sachdev, Jasgit C ^a   Jahanzeb, Mohammad ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

HER1 EGFR; Monoclonal antibodies; Resistance; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ANASTROZOLE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; LETROZOLE; MONOCLONAL ANTIBODY; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE; RIDAFOROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APOPTOSIS; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPERGLYCEMIA; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; RASH; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; UNITED STATES;

EID: 84856060985     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.07.001     Document Type: Review

References (123)

1. M. Scaltriti, J. Baselga The epidermal growth factor receptor pathway: a model for targeted therapy Clin Cancer Res 12 2006 5268 5272 (Pubitemid 44497237)
2. L.N. Klapper, M.H. Kirschbaum, M. Sela Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Adv Cancer Res 77 2000 25 79 (Pubitemid 29439302)
3. D. Graus-Porta, R.R. Beerli, J.M. Daly ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1997 1647 1655 (Pubitemid 27151960)
4. M.F. Press, D.J. Slamon, K.J. Flom Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 2002 3095 3105 (Pubitemid 34791099)
5. D.J. Slamon, G.M. Clark, S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
6. D.J. Slamon, W. Godolphin, L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
7. M.M. Moasser The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 26 2007 6469 6487 (Pubitemid 47530601)
8. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
9. R. Nahta, L.X. Yuan, B. Zhang Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 2005 11118 11128 (Pubitemid 41713383)
10. Y. Lu, X. Zi, Y. Zhao Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 2001 1852 1857 (Pubitemid 34048651)
11. N.L. Spector, K.L. Blackwell Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 2009 5838 5847
12. J. Mendelsohn, J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799 (Pubitemid 46606324)
13. J. Baselga, C.L. Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445 2459 (Pubitemid 47050835)
14. R.D. Mass, M.F. Press, S. Anderson Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 6 2005 240 246 (Pubitemid 47050800)
15. A.D. Seidman, D. Berry, C. Cirrincione Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 2008 1642 1649
16. J. Baselga, X. Carbonell, N.J. Castaneda-Soto Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Clin Oncol 23 2005 2162 2171 (Pubitemid 46218708)
17. C.L. Vogel, M.A. Cobleigh, D. Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726 (Pubitemid 34111379)
18. M.A. Cobleigh, C.L. Vogel, D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648 (Pubitemid 29415219)
19. M.D. Pegram, G.E. Konecny, C. O'Callaghan Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 2004 739 749 (Pubitemid 38771819)
20. H.J. Burstein, A. Keshaviah, A.D. Baron Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study Cancer 110 2007 965 972 (Pubitemid 47312860)
21. M. Jahanzeb, J.E. Mortimer, F. Yunus Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer Oncologist 7 2002 410 417 (Pubitemid 35266133)
22. M. Marty, F. Cognetti, D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274 (Pubitemid 46207001)
23. D. Yamamoto, S. Iwase, K. Kitamura A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial Cancer Chemother Pharmacol 61 2008 509 514 (Pubitemid 350275987)
24. L.B. Petruzelka, V. Ganju, D. Becquart Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): recent analysis of the results with a median follow-up of 44 months J Clin Oncol 28 2010 [abstract 1077]
25. D.A. Yardley, H.A. Burris III, L. Simons A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer Clin Breast Cancer 8 2008 425 431
26. M. Andersson, E. Lidbrink, K. Bjerre Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study J Clin Oncol 29 2011 264 271
27. G. Von Minckwitz, B.A. du, M. Schmidt Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 2009 1999 2006
28. R. Bartsch, C. Wenzel, S.P. Gampenrieder Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer Cancer Chemother Pharmacol 62 2008 903 910
29. A. Seidman, C. Hudis, M.K. Pierri Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221 (Pubitemid 34177427)
30. G.A. Viani, S.L. Afonso, E.J. Stefano Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 2007 153
31. G. Metro, M. Mottolese, A. Fabi HER-2-positive metastatic breast cancer: trastuzumab and beyond Expert Opin Pharmacother 9 2008 2583 2601
32. M. Scaltriti, F. Rojo, A. Ocana Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst 99 2007 628 638 (Pubitemid 47073544)
33. G.D. Lewis Phillips, G. Li, D.L. Dugger Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 2008 9280 9290
34. I.E. Krop, M. Beeram, S. Modi Phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J Clin Oncol 28 2010 398 405
35. Krop I, LoRusso P, Miller KD, et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2 metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at: the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; [abstract 5090].
36. P. LoRusso, I.E. Krop, H.A. Burris III Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy J Clin Oncol 28 15S 2010 [abstract 1016]
37. D.B. Agus, R.W. Akita, W.D. Fox Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137 (Pubitemid 41039113)
38. M.C. Franklin, K.D. Carey, F.F. Vajdos Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5 2004 317 328 (Pubitemid 38482068)
39. D.B. Agus, M.S. Gordon, C. Taylor Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol 23 2005 2534 2543 (Pubitemid 47050843)
40. N. Yamamoto, Y. Yamada, Y. Fujiwara Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors Jpn J Clin Oncol 39 2009 260 266
41. W. Scheuer, T. Friess, H. Burtscher Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res 69 2009 9330 9336
42. R. Nahta, M.C. Hung, F.J. Esteva The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2004 2343 2346 (Pubitemid 38523885)
43. J. Baselga, K.A. Gelmon, S. Verma Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 2010 1138 1144
44. Y. Nagata, K.H. Lan, X. Zhou PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127 (Pubitemid 39485684)
45. X.F. Le, F.X. Claret, A. Lammayot The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition J Biol Chem 278 2003 23441 23450 (Pubitemid 36830161)
46. C.A. Ritter, M. Perez-Torres, C. Rinehart Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res 13 2007 4909 4919 (Pubitemid 47294799)
47. Y. Yarden, M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137 (Pubitemid 33674041)
48. H.A. Burris III Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib Oncologist 9 suppl 3 2004 10 15
49. A. Sassen, J. Rochon, P. Wild Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients Breast Cancer Res 10 2008 R2
50. A.J. Tevaarwerk, J.M. Kolesar Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer Clin Ther 31 Pt 2 2009 2332 2348
51. W. Xia, R.J. Mullin, B.R. Keith Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
52. ® (lapatinib) tablets [package insert] 2010 GlaxoSmithKline Research Triangle Park, NC
53. C.E. Geyer, J. Forster, D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743 (Pubitemid 46021510)
54. D. Cameron, M. Casey, C. Oliva Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial Oncologist 15 2010 924 934
55. H.L. Gomez, D.C. Doval, M.A. Chavez Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer J Clin Oncol 26 2008 2999 3005
56. A. Di Leo, H.L. Gomez, Z. Aziz Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol 26 2008 5544 5552
57. N.U. Lin, L.A. Carey, M.C. Liu Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 26 2008 1993 1999
58. N.U. Lin, V. Dieras, D. Paul Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 2009 1452 1459
59. C. Dang, N. Lin, B. Moy Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea J Clin Oncol 28 2010 2982 2988
60. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract S3-3].
61. A. Ocana, E. Amir Irreversible pan-ErbB.tyrosine kinase inhibitorsbreast cancer: current status and future directions Cancer Treat Rev 35 2009 685 691
62. D.W. Rusnak, K. Affleck, S.G. Cockerill The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res 61 2001 7196 7203 (Pubitemid 32946515)
63. F.A. Eskens, C.H. Mom, A.S. Planting A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours Br J Cancer 98 2008 80 85
64. N. Minkovsky, A. Berezov BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors Curr Opin Investig Drugs 9 2008 1336 1346
65. T.A. Yap, L. Vidal, J. Adam Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors J Clin Oncol 28 2010 3965 3972
66. T. Hickish, D. Wheatley, N. Lin Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab Cancer Res 69 2009 2191 2194
67. S.K. Rabindran, C.M. Discafani, E.C. Rosfjord Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res 64 2004 3958 3965 (Pubitemid 38697310)
68. H.R. Tsou, E.G. Overbeek-Klumpers, W.A. Hallett Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J Med Chem 48 2005 1107 1131 (Pubitemid 40270454)
69. E.L. Kwak, R. Sordella, D.W. Bell Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci U S A 102 2005 7665 7770
70. K.K. Wong, P.M. Fracasso, R.M. Bukowski A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors Clin Cancer Res 15 2009 2552 2558
71. H.J. Burstein, Y. Sun, L.Y. Dirix Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer J Clin Oncol 28 2010 1301 1307
72. Chow L, Gupta S, Hershman DL, et al. Efficacy and safety of neratinib (HKI-272) in combination with paclitaxel in Her2+ metastatic breast cancer. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract P3-14-04].
73. Staroslawska E, Dirix L, Luu T, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2+ metastatic breast cancer Pretreated with anti-HER2 therapy. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract P3-14-05].
74. Saura C, Martin M, Moroose R, et al. Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors: a phase 1/2 study. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; [abstract 5108].
75. O. Rixe, S.X. Franco, D.A. Yardley A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer Cancer Chemother Pharmacol 64 2009 1139 1148
76. J.P. Crown, H.A. Burris III, F. Boyle Pooled analysis of diarrhea events in patients with cancer treated with lapatinib Breast Cancer Res Treat 112 2008 317 325
77. Burstein HJ, Sun Y, Dirix L, et al. Gastrointestinal and cardiovascular safety profiles of neratinib monotherapy in patients with advanced ErbB2-positive breast cancer. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; [abstract 5096].
78. B. Moy, P.E. Goss Lapatinib-associated toxicity and practical management recommendations Oncologist 12 2007 756 765 (Pubitemid 47328219)
79. M.H. Schuler, M.M. Uttenreuther-Fischer, M.J. Piccart-Gebhart BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies J Clin Oncol 28 15S 2010 [abstract 1065]
80. K. Gunzer, H. de Mont-Serrat, M.M. Uttenreuther-Fischer Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy J Clin Oncol 28 15S 2010 [abstract 1072]
81. H. Azim, H.A. Azim Jr, B. Escudier Trastuzumab versus lapatinib: the cardiac side of the story Cancer Treat Rev 35 2009 633 638
82. E.A. Perez, M. Koehler, J. Byrne Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 2008 679 686 (Pubitemid 351810568)
83. P. Perrotte, T. Matsumoto, K. Inoue Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 1999 257 265 (Pubitemid 29085177)
84. C.K. Osborne, R. Schiff Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer Breast 12 2003 362 367 (Pubitemid 38008644)
85. G.E. Konecny, M.D. Pegram, N. Venkatesan Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 2006 1630 1639 (Pubitemid 43259947)
86. B. Dave, I. Migliaccio, M.C. Gutierrez Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers J Clin Oncol 29 2011 166 173
87. K.L. Blackwell, H.J. Burstein, A.M. Storniolo Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 2010 1124 1130
88. Blackwell KL, Burstein HJ, Sledge GW, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; [abstract 61].
89. F.J. Esteva, S. Franco, M.K. Hagan Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer J Clin Oncol 28 15S 2010 [abstract 1046]
90. R. Swaby, K. Blackwell, Z. Jiang Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study J Clin Oncol 27 15S 2009 [abstract 1004]
91. K.A. Gelmon, P. Fumoleau, S. Verma Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy J Clin Oncol 25 15S 2008 [abstract 1026]
92. Gianni L, Pienkowski T, Im YH, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract S3-2].
93. K. Miller, L. Gianni, F. Andre A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T) J Clin Oncol 28 15S 2010 [abstract 1012]
94. G.E. Konecny, Y.G. Meng, M. Untch Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 2004 1706 1716 (Pubitemid 38435562)
95. J.M. du Manoir, G. Francia, S. Man Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts Clin Cancer Res 12 2006 904 916 (Pubitemid 43259873)
96. M.D. Pegram, C. Yeon, N.C. Ku Phase I combined biological therapy of breast cancer using 2 humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF) Breast Cancer Res Treatment 88 Suppl 1 2010 S124 [abstract 3039]
97. Hurvitz SA, Pegram MD, Lin L-S, et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; [abstract 6094].
98. H.S. Rugo, S. Franco, P. Munster A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC) J Clin Oncol 26 15S 2008 [abstract 1042]
99. J. Shou, S. Massarweh, C.K. Osborne Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 2004 926 935 (Pubitemid 38868139)
100. A. Prat, J. Baselga The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Nat Clin Pract Oncol 5 2008 531 542
101. B. Kaufman, J.R. Mackey, M.R. Clemens Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 2009 5529 5537
102. S. Johnston, J. Pippen Jr, X. Pivot Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 2009 5538 5546
103. L.S. Schwartzberg, S.X. Franco, A. Florance Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer Oncologist 15 2010 122 129
104. A. Lipton, S.M. Ali, K. Leitzel Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer J Clin Oncol 20 2002 1467 1472 (Pubitemid 34260524)
105. R.J. Pietras, J. Arboleda, D.M. Reese HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 1995 2435 2446
106. F.L. Chen, W. Xia, N.L. Spector Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors Clin Cancer Res 14 2008 6730 6734
107. Jegg A-M, Ward T, Iorns E, et al. Activation of SRC and MAPK mediates resistance to lapatinib in ER-/ERBB2+ breast cancer. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract P3-14-14].
108. F. Dalenc, M. Campone, P. Hupperets Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial J Clin Oncol 28 15S 2010 [abstract 1013]
109. P.H. Morrow, G.M. Wulf, D.J. Booser Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer J Clin Oncol 28 15S 2010 [abstract 1014]
110. G.H. Jerusalem, A. Fasolo, C. Massacesi Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): pooled data of extension cohorts of phase Ib/II studies J Clin Oncol 28 15S 2010 [abstract 1041]
111. G. Jerusalem, A. Fasolo, V. Dieras Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer Breast Cancer Res Treat 125 2011 447 455
112. D.A. Yardley, M. Seiler, I. Ray-Coquard Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter phase 2 clinical trial Cancer Res 69 Suppl 24 2009 [abstract 3091]
113. A. Citri, B.S. Kochupurakkal, Y. Yarden The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention Cell Cycle 3 2004 51 60 (Pubitemid 40268587)
114. A. Citri, J. Gan, Y. Mosesson Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation EMBO Rep 5 2004 1165 1170 (Pubitemid 40103611)
115. S. Modi, A.T. Stopeck, H.M. Linden HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab Clin Cancer Res 17 2011 5132 5139
116. S. Modi, C. Saura, C.A. Henderson Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer J Clin Oncol 29 Suppl 2011 [abstract 590]
117. Modi S, Ismail-Khan R, Munster P, et al. Phase 1 dose-escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2+ metastatic breast cancer. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract P3-14-02].
118. J.J. Kovacs, P.J. Murphy, S. Gaillard HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol Cell 18 2005 601 607 (Pubitemid 40726236)
119. L. Whitesell, S.L. Lindquist HSP90 and the chaperoning of cancer Nat Rev Cancer 5 2005 761 772 (Pubitemid 41400776)
120. N.W. Peacock, S.F. Jones, D.A. Yardley A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib J Clin Oncol 28 2010 1115
121. A. Camirand, Y. Lu, M. Pollak Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells Med Sci Monit 8 2002 BR521 BR526
122. Untch M, Fasching PA, Konecny GE, et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow-up data of the TECHNO trial. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract P1-11-03].
123. Untch M, Loibl S, Bischoff J, et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX; [abstract S3-1].